Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Medical technology company Outset Medical Inc's (NASDAQ: OM) Chief Financial Officer, Rebecca Chambers, is set to resign from the position to pursue other opportunities, effective July 16, 2021. Outset has named Nabeel Ahmed, Vice President, Finance, as the interim CFO, effective after Rebecca's departure.

Outset Medical CFO To Step Down; Sees 109% Revenue Growth In Q2

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Rebecca Chambers will step down from her position as Chief Financial Officer to pursue other opportunities, effective July 16, 2021. Nabeel Ahmed, current Vice President, Finance, has been named Interim Chief Financial Officer effective upon Ms. Chambers' departure. Outset annou

Outset Medical Announces Departure of CFO and Appointment of Nabeel Ahmed as Interim CFO

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a dialysis technology innovator, today announced the appointment of Jean-Olivier Racine as Chief Technology Officer. In this new role, Racine will oversee the strategic advancement of Outset's product technology, amplifying the company's data-driven innovation engine to further elevate the patient care experience and drive operating efficiencies for providers. Racine joins Outset Medical with more than two decades

Outset Medical Welcomes Jean-Olivier Racine as Chief Technology Officer

SAN JOSE, Calif.--(BUSINESS WIRE)--Strive Health, the national leader in value-based kidney care, and Outset Medical, Inc. (Nasdaq: OM), a dialysis technology innovator, announced a collaboration to help further the companies' efforts to change the kidney care paradigm. A rapidly growing organization focused on slowing kidney disease progression and preventing costly hospitalizations through a proprietary whole-patient solution, Strive Health will use Outset's Tablo Hemodialysis System to expan

Health Tech Innovators Strive Health and Outset Medical Collaborate to Reinvent Kidney Care

SAN JOSE, Calif.--(BUSINESS WIRE)--Satellite Healthcare, a leading national not-for-profit kidney care company and Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind dialysis technology, announced a joint effort to drive home hemodialysis adoption within Satellite Healthcare's nationwide network of dialysis centers. As part of the multi-year sales agreement, Satellite Healthcare will purchase and utilize Tablo systems for home hemodialysis. Further, t

Satellite Healthcare and Outset Medical Announce Multi-Year Agreement to Increase Home Dialysis Penetration

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 7:30am PT / 10:30am ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the Outs

Outset Medical to Present at Goldman Sachs 42nd Annual Global Healthcare Conference

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, today announced the appointment of Katie Szyman to its board of directors. Szyman, currently Corporate Vice President and General Manager of Critical Care at Edwards Lifesciences, brings more than 30 years of global medtech leadership experience. With a focus on driving sustainable, high-growth revenue,

Outset Medical Appoints MedTech Executive Katie Szyman to Board of Directors

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, has joined Moving Health Home, a coalition of innovative healthcare companies seeking to fundamentally change the way policymakers think about home healthcare. Founding members include Amazon Care, Amwell, Dispatch Health, Home Instead, Landmark Health and Signify Health, among others. Established in March 2021

Outset Medical Joins Healthcare Innovation Coalition Focused on Shaping the Future of Home-Based Care

Outset Medical, Inc. (OM) CEO Leslie Trigg on Q1 2021 Results - Earnings Call Transcript

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2021. Recent Highlights Recorded net revenue of $22.9 million in the first quarter of 2021, a 219% increase compared to $7.2 million in the first quarter of 2020 Achieved gross margin of 1.3% for the first quarte

Outset Medical Reports First Quarter 2021 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021 at 11:45am PT / 2:45pm ET. A live and archived webcast of the fireside chat will be available on the “Investors” section of the Outset we

Outset Medical to Present at BofA Securities 2021 Virtual Health Care Conference

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Wednesday, May 5, 2021. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Rebecca Chambers, Chief Financial Officer, will host a

Outset Medical to Report First Quarter 2021 Financial Results on Wednesday, May 5, 2021

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the closing of its previously announced underwritten public offering of 2,945,864 shares of its common stock sold by Outset and 3,890,723 shares of its common stock sold by certain of its stockholders at a public offering price of $53.50 per share, which amounts include 891,728 share

Outset Medical Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Outset Medical Inc (NASDAQ: OM) has priced an underwritten public offering of 2.5 million common shares sold by the company and some 3.4 million shares sold by certain of its stockholders at $53.50 per share. The offer price is at a 4% discount from the last close price of $55.6 on Thursday.

Outset Medical Prices Equity Offering At $53.50 Per Share

SAN JOSE, Calif.--(BUSINESS WIRE)--The U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) have named Outset Medical's Tablo Hemodialysis System® one of seven winners in Round 2 of the KidneyX COVID-19 Kidney Care Challenge, recognizing innovative solutions for safely delivering kidney care during the pandemic. Specifically designed to simplify dialysis treatment for patients and providers, Tablo is a first-of-its-kind enterprise solution that lowers

Outset Medical Named a Winner in Round 2 of the KidneyX COVID-19 Kidney Care Challenge

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the pricing of an underwritten public offering of 2,500,000 shares of its common stock sold by Outset and 3,444,859 shares of its common stock by certain of its stockholders at a public offering price of $53.50 per share. In addition, Outset and such selling stockholders granted the

Outset Medical Announces Pricing of Primary and Upsized Secondary Public Offering

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today the commencement of a proposed underwritten public offering of 2,500,000 shares of its common stock by Outset and 2,500,000 shares of its common stock by certain of its stockholders. In addition, Outset and such selling stockholders expect to grant the underwriters a 30-day option to

Outset Medical Announces Primary and Secondary Offering of Common Stock

Outset Medical has seen continued commercial traction and provides a comforting guidance for 2021. While the guidance is strong, I still believe it might be conservative given the recent commercial traction and potential of the home market.

Outset Medical: Continues To Impress

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), the medical technology company that pioneered the Tablo Hemodialysis System, a first-of-its-kind device to reduce the cost and complexity of dialysis, is strengthening its consumer focus with the appointment of Andrea Saia to its board of directors. Saia's background in building iconic global brands will help Outset's efforts to grow the home dialysis market and empower patients to take better charge of their healt

Outset Medical Appoints Global Consumer Brand Builder Andrea Saia to Board of Directors

American Well Corporation

Athira Pharma

Broadstone Net Lease

COMPASS Pathways

Coupang

Dyne Therapeutics

GreenBox POS

908 Devices

Metacrine

Poshmark

Pactiv Evergreen

StepStone Group

Sumo Logic

Vitru Limited

The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14.

U.S. IPO Week Ahead: The Spring IPO Market Starts To Thaw In An 8 IPO Week

Outset Medical, Inc. (OM) CEO Leslie Trigg on Q4 2020 Results - Earnings Call Transcript

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights Recorded net revenue of $17.2 million in the fourth quarter and $49.9 million for the full year of 2020, representing 143% and 231% increases respectively, over the corresponding periods

Outset Medical Reports Fourth Quarter and Full Year 2020 Financial Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Tuesday, March 9, 2021. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chief Executive Officer, and Rebecca Chambers, Chief Financial Offic

Outset Medical to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021

ResMed

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader; VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions; and Tivic Health, a bioelec

Outset Medical Appoints Karen Drexler to Board of Directors

Discover how Outset Medical is making dialysis easier and cheaper.

News for Outset Medical Stock (OM)